New Workflow Is First End-to-End Solution For Extrusion-Based Drug Implant Production
Posted: 27 July 2017 | Thermo Fisher Scientific | No comments yet
Thermo Scientific Pharma mini implant line is an automated, integrated system designed for continuous production of drug implants…
To meet growing demand for innovative drug delivery systems in the pharmaceutical industry, drug formulation scientists can now use the first commercially available, fully-integrated solution for polymer-based drug implant development and production using hot melt extrusion (HME). This new drug development workflow provides pharmaceutical manufacturers with a complete end-to-end manufacturing line from a single supplier.
The Thermo Scientific Pharma mini implant line is built around the Thermo Scientific Pharma mini HME twin-screw micro compounder. It provides drug developers, process manufacturing scientists and engineers with a continuous and fast production process designed to improve product quality, maximise operator safety and reduce the risk of contamination. This integrated production line is also designed to allow contract research and manufacturing organisations (CRO/CMO) to develop and optimise small-scale formulations before engaging in larger-scale production.
“With a single subcutaneous injection, advanced drug implants can release a therapeutic substance that can provide patients with improved drug compliance, effective disease treatment or controlled hormonal regulation for weeks or even months,” said Hanna Granö-Fabritius, senior business director, material characterization for Thermo Fisher Scientific. “Pharmaceutical manufacturers are seeking fast, reliable solutions for continuous production of novel drug delivery systems. Our new, automated implant line offers a hot melt extrusion solution designed to minimize formulation development time.”
The Thermo Scientific Pharma mini implant line incorporates a range of components in an innovative configuration. In addition to the Pharma mini HME micro compounder, components include:
- A containment valve to add the active pharmaceutical ingredient (API) and the polymer, designed to protect the operator from exposure to the API and preventing contamination of the API;
- A gravimetric feeder to deliver the API/polymer into the micro compounder for heating and mixing before the melt is extruded through a die that creates a continuous filament;
- New bi-axial lasers that measure the thickness or diameter of the filament to adjust the stretching or “take-off” speed of the conveyor belt
- Proprietary equipment that cuts the filament to a desired implant length while maintaining “roundness” without deforming the implant shape.
For more information on the Thermo Scientific Pharma mini implant line, please visit www.thermofisher.com/implantline.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.
For more information, please visit www.thermofisher.com.
Related topics
Drug Development, Drug Manufacturing, Drug Safety, Product Quality Lifecycle Implementation (PQLI), QA/QC
